Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in pediatric aHUS
NCT03131219Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2017
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of ravulizumab in atypical hemolytic uremic syndrome (aHUS), sponsored by Alexion Pharmaceuticals. Primary endpoint: Percentage Of Complement Inhibitor Treatment-naïve Participants With Complete Thrombotic Microangiopathy (TMA) Response at Week 26. Started Aug 2017; status: completed.
02
Drugs
ravulizumab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NCT03131219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03131219.